Methylation Analysis of 5’UTR Promoter Region of DBC2 as a Biomarker in the Peripheral Bloods of Some Iranian Women with Sporadic Breast Cancer

Document Type: Original Research

Authors

1 Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran

2 Dept. of Medical Genetics, School of Medicine, Tarbiat Modares University, Tehran, Iran

3 Dept. of Surgery, School of Medicine, Tehran University of Medical Sciences, Tehran ,Iran

4 Sarem Cell Research Center (SCRC) & Dept. of Medical Genetics, Sarem Hospital, Tehran,Iran

Abstract

Background and Objective: The DBC2 (deleted in breast cancer 2) or RhoBTB2 (Located on 8p21) is a tumor suppressor gene associated with tumorigenesis. Mutational studies of DBC2 at its promoter region in breast cancer revealed an important role for epigenetic changes contributing to its low expression. Epigenetic changes through hypermethylation of the promoter can cause the inactivation of DBC2 gene. The purpose of this study was to investigate methylation pattern of DBC2 gene in the peripheral blood of 40 Iranian women with breast cancer and its comparison with healthy women.
Material & Methods: We used peripheral blood samples from 40 patients with sporadic breast cancer and 40 normal individuals. Analysis of the methylation statues of DBC2 promoter region was done by MSP (Methylation Specific PCR ) technique on the DNA extracted from the blood samples. The results were validated by sequencing. The methylation status was then correlated with the clinicopathological parameters of breast cancer patients.
Results:Methylation pattern was detected in 60% of the patients, whereas 25% of the normal individuals demonstrated a positive methylation pattern (P ≤ 0.01, odd ratio : 2.143). No significant correlation was obtained between methylated DBC2 and cliniclpathological parameters.
Discussion: Aberrant hypermethylation was observed preferentially in the patients. These findings along with the previous studies, propose that abnormal methylation pattern in DBC2 promoter region may be one of the main reasons for low expression of DBC2 in breast cancer and this hypermethylation pattern could play a fundamental role in the breast tumorigenesis.
 

Keywords


  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90. 
  2. RezaianzadehA, Heydari ST, Hosseini H, Haghdoost AA, BarootiE,Lankarani KB. Prevalence of Breast Cancer in a Defined Population ofIran. Iran Red Crescent Med J 2011; 13(9): 647–50.
  3. Behjati F, Atri M, Najmabadi H, Nouri K, Zamani M, Mehdipour P. Prognostic value of chromosome 1 and 8 copy number in invasive ductal breast carcinoma among Iranian women: An interphase fish analysis. PatholOncol Res 2005; 11(3):157-63.
  4. Pujol P, This P, Noruzinia M, Stoppa-Lyonnet D, Maudelonde T. Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens? Bulletin du cancer 2004; 91(7-8):583.
  5. Bae YK, Shim YR, Choi JH, Kim MJ, Gabrielson E, Lee SJ, et al. Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat 2005; 37(4):233-40.
  6. Matsumoto M, Kawakami K, Enokida H, Toki K, Matsuda R, Chiyomaru T, et al. CpGhypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancer. Cancer 2010; 26:241-7.
  7. Radpour R, Barekati Z, Kohler C, Schumacher MM, Grussenmeyer T, Jenoe P, et al. Integrated Epigenetics of Human Breast Cancer: Synoptic Investigation of Targeted Genes, MicroRNAs and Proteins upon Demethylation Treatment. PloS One 2011; 6(11):e27355.
  8. Van De Voorde L, Speeckaert R, Van Gestel D, Bracke M, De Neve W, Delanghe J, et al. DNA methylation-based biomarkers in serum of patients with breast cancer. Mutation Res 2012; 751(2). p.304-25.
  9. Freeman SN, Cress WD. RhoBTB2 (DBC2) comes of age as a multifunctional tumor suppressor. Cancer Biol Ther 2010; 10(11):1123-5.
  10. Gu Cho Y, Joon Choi B, Jae Kim C, Hwi Song J, Zhang C, Woo Nam S, et al. Genetic analysis of the DBC2 gene in gastric cancer. Acta Oncol 2007; 47(3):366-71.
  11. Hamaguchi M, Meth JL, Von Klitzing C, Wei W, Esposito D, Rodgers L, et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proceedings of the National Academy of Sciences. 2002; 99(21):13647.
  12. Mao H, Qu X, Yang Y, Zuo W, Bi Y, Zhou C, et al. A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer. Mol Carcinog 2010; 49(3):283-9.
  13. Siripurapu V, Meth J, Kobayashi N, Hamaguchi M. DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways. J Mol Biol 2005; 346(1):83-9.
  14. Collado D, Yoshihara T, Hamaguchi M. DBC2 resistance is achieved by enhancing 26S proteasome-mediated protein degradation. Biochem Biophys Res Commu 2007; 360(3):600-3.
  15. Mao H, Zhang L, Yang Y, Sun J, Deng B, Feng J, et al. RhoBTB2 (DBC2) functions as a tumor suppressor via inhibiting proliferation, preventing colony formation and inducing apoptosis in breast cancer cells. Gene 2011; 486:74–80.
  16. Ling LJ, Lu C, Zhou GP, Wang S. Ectopic expression of RhoBTB2 inhibits migration and invasion of human breast cancer cells. Cancer Biol Ther 2011; 10(11):1115-22.
  17. Mirzaei M, Noruzinia M, karbassian H, shafeghati Y, Keyhanee M, Bidmeshki-pour A. Evaluation of Methylation Status in the 5'UTR promoter region of the DBC2 gene as a biomarker in sporadic breast cancer.Cell J 2012; 14:19-24.
  18. Ohadi M, Totonchi M, Maguire P, Lindblom A, Habibi R, AfshinAlavi B, et al. Mutation analysis of the DBC2 gene in sporadic and familial breast cancer. Acta Oncol 2007; 46(6):770-2
  19. Shi Y, Chen JY, Yang J, Li B, Chen ZH and Xiao CG: DBC2 gene is silenced by promoter methylation in bladder cancer.Urol Oncol. 2008; 26: 465-469.
  20. Schenková K, RiveroF . RHOBTB2 (Rho-related BTB domain containing 2). Atlas Genet Cytogenet Oncol Haematol. 2009; 3(11).
  21. Bi Y, Wei L, Mao HT, Zhang L, Zuo WS. Expressions of Fas, CTLA-4 and RhoBTB2 genes in breast carcinoma and their relationship with clinicopathological factors. Zhonghuazhongliuza  2008; 30(10):749.
  22. Li WW, Boyd J. Estrogen receptor-{alpha} mediated silencing of DBC2 through promoter hypermethylation in breast cancer cells. Proceedings of the American Association for Cancer Research. 2004; 2004(1):840.
  23. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59(1):67.
  24. Hu XC, Wong IH, Chow LW. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Oncol Rep 2003; 10(6):1811.
  25. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001; 61(3):900.